Published on in Vol 11, No 7 (2022): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/34206, first published .
Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)

Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)

Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)

Michael Feher 1*, MD;  William Hinton 1*, MSc;  Anna Forbes 1, MBChB;  Neil Munro 2*, DPhil;  Mark Joy 1, PhD;  David Wheeler 3*, MD;  Simon de Lusignan 1*, MD

1 Clinical Informatics and Health Outcomes Research Group, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford , GB

2 Clinical Informatics, University of Surrey , Guildford , GB

3 Department of Renal Medicine, University College London , London , GB

*these authors contributed equally

Corresponding Author:

  • Michael Feher, MD
  • Clinical Informatics and Health Outcomes Research Group
  • Nuffield Department of Primary Care Health Sciences
  • University of Oxford
  • Eagle House, Walton Well Road
  • Oxford
  • GB
  • Phone: 44 1865 289
  • Email: michael.feher@phc.ox.ac.uk